Irbesartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 63629-7468

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Irbesartan And Hydrochlorothiazide (NDC 63629-7468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Irbe H Figure1a

A line graph showing the relationship between baseline systolic blood pressure (SBP) in mmHg on the x-axis and the percentage of subjects with SBP less than 140 mmHg on the y-axis. The graph includes multiple lines representing different studies comparing Irbesartan (Irb.) and Hydrochlorothiazide (HCTZ) treatments in various study groups.*

FDA Label Image

Irbe H Figure1b

A line chart showing the percentage of patients with systolic blood pressure (SBP) less than 130 mmHg plotted against baseline SBP values in mmHg. The chart compares different studies labeled as Irb. HCTZ Study V, Irb. Study V, HCTZ Study V, Irb. HCTZ Study VI, and Irb. Study VI, each represented by distinct line styles on the graph.*

FDA Label Image

Irbe H Figure2a

A line graph depicting the percentage of diastolic blood pressure (DBP) below 90 mmHg versus baseline DBP (mmHg) for different studies involving Irbesartan (Irb), Hydrochlorothiazide (HCTZ), and their combination. The legend differentiates between Study V and Study VI for these treatments.*

FDA Label Image

Irbe H Figure2b

A line graph showing the percentage of patients with diastolic blood pressure (DBP) below 80 mmHg plotted against baseline DBP (mmHg). Multiple lines represent different study groups involving Irbesartan (Irb), Hydrochlorothiazide (HCTZ), and their combination across studies labeled V and VI.*

FDA Label Image

Irbe H Figure3

A scatter plot with a curve showing the relationship between Irbesartan dose (mg/day) on the x-axis and placebo-subtracted reduction in integrated systolic blood pressure (mmHg) on the y-axis. Data points are plotted with a fitted curve indicating the dose-response trend.*

FDA Label Image

Irbe H Figure4

A scatter plot with a fitted curve depicting the placebo-subtracted reduction in trough systolic blood pressure (mmHg) versus Irbesartan dose (mg/day), showing a nonlinear trend with reduction increasing with dose up to about 900 mg/day.*

FDA Label Image

Irbe H Hydrochlorothiazide

Chemical structure diagram of the active ingredient Irbesartan and Hydrochlorothiazide, showing molecular bonds and groups including sulfonamide, chlorine, and nitrogen atoms arranged in a complex ring structure.*

FDA Label Image

Irbe H Irbesartan

Chemical structure of the active ingredient Irbesartan depicted as a molecular diagram with its characteristic rings and functional groups.*

FDA Label Image

Label Image (Lbl636297468)

Label for Irbesartan and Hydrochlorothiazide tablets, USP 150 mg/12.5 mg, oral film-coated tablets. The label shows the NDC 63629-7468-01, manufactured by Bryant Ranch Prepack. Packaging indicates 30 tablets per bottle and includes storage instructions and dosage information.*

FDA Label Image

Lbl6362974682

Packaging label for Irbesartan Hctz 150/12.5 mg tablet, film coated, supplied by Bryant Ranch Prepack. The label indicates a package of 30 tablets with NDC 63629-7468-81 and includes storage instructions to keep at room temperature between 20°-25°C (68°-77°F). It also advises keeping drugs out of reach of children and references Avalid 150/12.5 mg tablet by Macleod Pharmaceuticals Ltd.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.